Program/Compound NX-217 · EU5 Launch
Phase III

Governance

Roles, approvals and a complete audit trail across the EU5 launch program.

Role & perspective

Local users only see their market across every module.

Program

Compound NX-217 · Phase III · EU5 Launch · 2026

Workspace: Global Brand Office

Approval queue

3 pending
2 approved this cycle

MLR, medical and brand sign-offs across global and local artefacts.

UK HCP Launch Deck v3

Requested by Grace Hollis · 2026-02-09 · Approver: Elena Marsh · 🇬🇧 United Kingdom

DE Patient Brochure (final art)

Requested by Sofia Lang · 2026-02-04 · Approver: Global MLR · 🇩🇪 Germany

Approved

IT Press Kit

Requested by Chiara Romano · 2026-02-07 · Approver: Global Comms · 🇮🇹 Italy

Master Objection-Handler v2

Requested by Global Marketing · 2026-01-28 · Approver: Medical Affairs

Approved

ES Congress Booth Concept

Requested by Lucía Vargas · 2026-02-10 · Approver: Brand Studio · 🇪🇸 Spain

Audit trail

Immutable, time-stamped log of every action across the program.

EMA portal EMA day-120 list of questions received for NX-217.

10 Feb 2026, 09:14 ·

DE

milestone

Owen Briggs Uploaded NICE Cost-Effectiveness Model v4.xlsx.

08 Feb 2026, 16:42 ·

UK

upload

System New High-impact risk auto-created on UK Launch Supply.

06 Feb 2026, 11:05 ·

UK

risk

Elena Marsh Approved Global HCP Campaign Toolkit for local adaptation.

03 Feb 2026, 08:30

approval

Julien Moreau Pre-meeting with HAS — likely SMR=Important, ASMR IV target.

29 Jan 2026, 14:22 ·

FR

comment

Markus Hahn AMNOG dossier locked and sent to G-BA.

25 Jan 2026, 10:11 ·

DE

milestone